El interés en corto de AngioDynamics da a los inversores una idea del grado en que los inversores apuestan por la caída de las acciones de AngioDynamics. Los datos de interés en corto se actualizan cada dos semanas.

AngioDynamics (NASDAQ:ANGO) Bolsa, Informe de interés en corto

AngioDynamics

AngioDynamics Inc designs manufactures, and sells medical, surgical, and diagnostic devices used by professional healthcare providers for the treatment of peripheral vascular disease and for use in oncology and surgical settings. Geographically, the company derives a majority of its revenue from the United States from sale of Med Tech and Med Device.

AngioDynamics Inc

ANGO WORLD HOLDINGS INC by ANGO World Holdings, Inc.

Angold Resources Ltd Ordinary Shares

Across the recent three months, 4 analysts have shared their insights on AngioDynamics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANGO#NASDAQ">ANGO</a>), expressing a variety of opinions spanning from bullish to bearish.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $13.5, a high estimate of $14.00, and a low estimate of $12.00. This current average has decreased by 1.82% from the previous average price target of $13.75. 
<img src="https://www.benzinga.com/files/images/story/2024/1733857211_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive AngioDynamics. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yi Chen</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$14.00</td>
<td>$14.00</td>
</tr>
<tr>
<td>Yi Chen</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$14.00</td>
<td>$14.00</td>
</tr>
<tr>
<td>William Plovanic</td>
<td>Canaccord Genuity</td>
<td>Lowers</td>
<td>Buy</td>
<td>$12.00</td>
<td>$13.00</td>
</tr>
<tr>
<td>Yi Chen</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$14.00</td>
<td>$14.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to AngioDynamics. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of AngioDynamics compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for AngioDynamics's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
For valuable insights into AngioDynamics's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/ANGO/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on AngioDynamics analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>About AngioDynamics</h2>
AngioDynamics Inc designs manufactures, and sells medical, surgical, and diagnostic devices used by professional healthcare providers for the treatment of peripheral vascular disease and for use in oncology and surgical settings. Geographically, the company derives a majority of its revenue from the United States from sale of Med Tech and Med Device.
<h3>AngioDynamics: Delving into Financials</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Revenue Challenges: AngioDynamics's revenue growth over 3 months faced difficulties. As of 31 August, 2024, the company experienced a decline of approximately -14.22%. This indicates a decrease in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: AngioDynamics's net margin is impressive, surpassing industry averages. With a net margin of -18.96%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): AngioDynamics's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -6.36% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): AngioDynamics's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of -4.19%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: With a below-average debt-to-equity ratio of 0.02, AngioDynamics adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>The Basics of Analyst Ratings</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

ANGO

In-Depth Examination Of 4 Analyst Recommendations For AngioDynamics

HC Wainwright &amp; Co. analyst Yi Chen reiterates AngioDynamics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANGO#NASDAQ">ANGO</a>) with a Buy and maintains $14 price target.

News

Price Target

Reiteration

HC Wainwright & Co. Reiterates Buy on AngioDynamics, Maintains $14 Price Target

WIIM

AngioDynamics shares are trading higher after the company announced the FDA has granted 510(k) clearance for its Nanoknife system for prostate tissue ablation.

Health Care

General

The FDA Has Granted 510(k) Clearance For AngioDynamics' Nanoknife System For Prostate Tissue Ablation

AngioDynamics, University College London Hospital Launch International Multi-Center Study On Long Term Effects Of Treatment With NanoKnife System

A downtrend has been apparent in AngioDynamics (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ango#NASDAQ">ANGO</a>) lately with too much selling pressure. The stock has declined 15.9% over the past four weeks. However, given the fact that it is now in oversold territory and Wall Street analysts are majorly in agreement about the company&#39;s ability to report better earnings than they predicted earlier, the stock could be due for a turnaround.
<h2>How to Determine if a Stock is Oversold</h2>
We use Relative Strength Index (RSI), one of the most commonly used technical indicators, for spotting whether a stock is oversold. This is a momentum oscillator that measures the speed and change of price movements.
RSI oscillates between zero and 100. Usually, a stock is considered oversold when its RSI reading falls below 30.
Technically, every stock oscillates between being overbought and oversold irrespective of the quality of their fundamentals. And the beauty of RSI is that it helps you quickly and easily check if a stock&#39;s price is reaching a point of reversal.
So, by this measure, if a stock has gotten too far below its fair value just because of unwarranted selling pressure, investors may start looking for entry opportunities in the stock for benefitting from the inevitable rebound.
However, like every investing tool, RSI has its limitations, and should not be used alone for making an investment decision.
<h2>Why a Trend Reversal is Due for ANGO</h2>
The RSI reading of 24.7 for ANGO is an indication that the heavy selling could be in the process of exhausting itself, so the stock could bounce back in a quest for reaching the old equilibrium of supply and demand.
<img alt="3-month RSI Chart for ANGO" class="chart" src="https://staticx-tuner.zacks.com/images/articles/charts/yseop/544/ANGO_RCI14.jpeg" style="height:auto; width:100%" title="" />
The RSI value is not the only factor that indicates a potential turnaround for the stock in the near term. On the fundamental side, there has been strong agreement among the sell-side analysts covering the stock in raising earnings estimates for the current year. Over the last 30 days, the consensus EPS estimate for ANGO has increased 0.8%. And an upward trend in earnings estimate revisions usually translates into price appreciation in the near term.
Moreover, ANGO currently has a Zacks Rank #2 (Buy), which means it is in the top 20% of more than the 4,000 stocks that we rank based on trends in earnings estimate revisions and EPS surprises. This is a more conclusive indication of the stock&#39;s potential turnaround in the near term.
<a href="https://www.zacks.com/stock/news/2347418/angiodynamics-ango-loses-15-86-in-4-weeks-here-s-why-a-trend-reversal-may-be-around-the-corner?cid=CS-BENZ-FT-tale_of_the_tape|rsi-2347418">To read this article on Zacks.com click here.</a>

Earnings

Technicals

Small Cap

Markets

Tech

Trading Ideas

AngioDynamics Loses -15.86% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Throughout the last three months, 4 analysts have evaluated AngioDynamics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANGO#NASDAQ">ANGO</a>), offering a diverse set of opinions from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $13.25, along with a high estimate of $14.00 and a low estimate of $12.00. A decline of 10.17% from the prior average price target is evident in the current average. 
<img src="https://www.benzinga.com/files/images/story/2024/1728054129_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive AngioDynamics. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>William Plovanic</td>
<td>Canaccord Genuity</td>
<td>Lowers</td>
<td>Buy</td>
<td>$12.00</td>
<td>$13.00</td>
</tr>
<tr>
<td>Yi Chen</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$14.00</td>
<td>$14.00</td>
</tr>
<tr>
<td>William Plovanic</td>
<td>Canaccord Genuity</td>
<td>Lowers</td>
<td>Buy</td>
<td>$13.00</td>
<td>$18.00</td>
</tr>
<tr>
<td>Yi Chen</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$14.00</td>
<td>$14.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to AngioDynamics. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of AngioDynamics compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of AngioDynamics's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into AngioDynamics's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/ANGO/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on AngioDynamics analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>Get to Know AngioDynamics Better</h2>
AngioDynamics Inc designs manufactures, and sells medical, surgical, and diagnostic devices used by professional healthcare providers for the treatment of peripheral vascular disease and for use in oncology and surgical settings. Geographically, the company derives a majority of its revenue from the United States from sale of Med Tech and Med Device.
<h3>Understanding the Numbers: AngioDynamics's Finances</h3>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Negative Revenue Trend: Examining AngioDynamics's financials over 3 months reveals challenges. As of 31 May, 2024, the company experienced a decline of approximately -22.06% in revenue growth, reflecting a decrease in top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of -18.95%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): AngioDynamics's ROE excels beyond industry benchmarks, reaching -6.34%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of -4.19%, the company showcases effective utilization of assets.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.02.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

4 Analysts Assess AngioDynamics: What You Need To Know

Canaccord Genuity analyst William Plovanic maintains AngioDynamics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANGO#NASDAQ">ANGO</a>) with a Buy and lowers the price target from $13 to $12.

Canaccord Genuity Maintains Buy on AngioDynamics, Lowers Price Target to $12

U.S. stocks traded lower toward the end of trading, with the Dow Jones index falling more than 200 points on Thursday.
The Dow traded down 0.54% to 41,969.72 while the NASDAQ fell 0.22% to 17,886.45. The S&amp;P 500 also fell, dropping, 0.30% to 5,692.35.
Check This Out: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/10/41161390/wall-streets-most-accurate-analysts-spotlight-on-3-defensive-stocks-delivering-high-divi">Wall Street&#8217;s Most Accurate Analysts Spotlight On 3 Defensive Stocks Delivering High-Dividend Yields</a>
Leading and Lagging Sectors Energy shares jumped by 1.3% on Thursday.
In trading on Thursday, consumer discretionary shares dipped by 1.4%.
Top Headline
U.S. natural-gas stocks rose 55 billion cubic feet during the week ended Sept. 27, compared to market estimates of a 57 bcf gain.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>Elevai Labs Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ELAB#NASDAQ">ELAB</a>) shares shot up 54% to $0.1317 after the company announced its subsidiary, Elevai Biosciences, filed two patent applications for its lead candidate, EL-22, aimed at treating muscle loss in obese patients.</li>
<li>Shares of Theriva Biologics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TOVX#NASDAQ">TOVX</a>) got a boost, surging 28% to $1.5843 after the company announced the Data and Safety Monitoring Committee&#8217;s review outcome for its Phase 1b/2a clinical trial of SYN-004. The DSMC has recommended the study proceed to enroll cohort 3.</li>
<li>AMTD Digital Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HKD#NYSE">HKD</a>) shares were also up, gaining 30% to $5.09.</li>
</ul>
Equities Trading DOWN
<ul>
<li>AngioDynamics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANGO#NASDAQ">ANGO</a>) shares dropped 18% to $6.31 following first-quarter results.</li>
<li>Shares of Levi Strauss &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LEVI#NYSE">LEVI</a>) were down 7% to $19.53 after the company reported worse-than-expected third-quarter sales results and issued its FY24 adjusted EPS guidance with its midpoint below estimates. The company began a strategic review for its Dockers brand and is exploring a potential sale or other strategic transactions.</li>
<li>Ingevity Corporation &nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NGVT#NYSE">NGVT</a>) was down, falling 13% to $32.73 as the company said John Fortson has departed as president and CEO and from the board of directors of the company, effective as of Oct. 2.</li>
</ul>
Commodities In commodity news, oil traded up 4.4% to $73.15 while gold traded up 0.3% at $2,676.60.
Silver traded up 1.3% to $32.33 on Thursday, while copper fell 2.2% to $4.5450.
Euro zone
European shares closed mostly lower today. The eurozone's STOXX 600 fell 0.93%, Germany's DAX fell 0.78% and France's CAC 40 fell 1.32%. Spain's IBEX 35 Index rose 0.07%, while London's FTSE 100 fell 0.10%.
Producer prices in the Eurozone rose 0.6% month-over-month in August compared to a revised 0.7% increase in July. The HCOB Eurozone composite PMI was revised higher to 49.6 in September versus a preliminary reading of 48.9.
The S&amp;P Global UK services PMI declined to 52.4 in September from 53.7 in the previous month, while German services PMI fell to 50.6 in September from 51.2 a month ago.
Asia Pacific Markets
Asian markets closed mixed on Thursday, with Japan's Nikkei 225 gaining 1.97%, Hong Kong's Hang Seng Index falling 1.47% and India's BSE Sensex dipping 2.10%.
The au Jibun Bank Japan services PMI was revised lower to 53.1 for September, versus a preliminary reading of 53.9.
Economics
<ul>
<li>U.S. initial jobless claims increased by 6,000 from the prior week to 225,000 during the week ended Sept. 28, compared to market estimates of 220,000.</li>
<li>The S&amp;P Global services PMI was revised lower to 55.2 in September compared to a preliminary reading of 55.4, and versus a reading of 55.7 in August.</li>
<li>The S&amp;P Global U.S. composite PMI sipped to 54 in September versus a preliminary reading of 54.4, and versus 54.6 in August.</li>
<li>U.S. natural-gas stocks rose 55 billion cubic feet during the week ended Sept. 27, compared to market estimates of a 57 bcf gain.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/10/41160677/top-3-consumer-stocks-which-could-rescue-your-portfolio-this-quarter">Top 3 Consumer Stocks Which Could Rescue Your Portfolio This Quarter</a></li>
</ul>

Equities

Eurozone

Commodities

Intraday Update

ELAB

LEVI

NGVT

TOVX

Nasdaq Moves Lower; Levi Strauss Shares Slide

<h3>Gainers</h3>
<ul>
<li>Theriva Biologics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/TOVX#AMEX">TOVX</a>) shares moved upwards by 33.5% to $1.66 during Thursday's regular session. The market value of their outstanding shares is at $2.2 million. </li>
<li>Verrica Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRCA#NASDAQ">VRCA</a>) shares rose 31.53% to $1.46. The company's market cap stands at $62.2 million. </li>
<li>Bone Biologics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BBLG#NASDAQ">BBLG</a>) stock rose 30.98% to $1.99. The company's market cap stands at $3.5 million. </li>
<li>OS Therapies (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/OSTX#AMEX">OSTX</a>) stock increased by 20.96% to $3.52. The company's market cap stands at $73.5 million. </li>
<li>TransCode Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNAZ#NASDAQ">RNAZ</a>) stock rose 20.84% to $0.6. The market value of their outstanding shares is at $10.3 million. </li>
<li>Cue Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CUE#NASDAQ">CUE</a>) stock rose 17.26% to $0.86. The company's market cap stands at $51.7 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Windtree Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WINT#NASDAQ">WINT</a>) shares decreased by 21.5% to $1.13 during Thursday's regular session. The market value of their outstanding shares is at $1.8 million. </li>
<li>AngioDynamics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANGO#NASDAQ">ANGO</a>) stock declined by 17.13% to $6.34. The company's market cap stands at $257.6 million. The company's, Q1 earnings came out today. </li>
<li>Soligenix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNGX#NASDAQ">SNGX</a>) stock fell 16.64% to $4.06. The company's market cap stands at $9.2 million. </li>
<li>TNF Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNFA#NASDAQ">TNFA</a>) stock decreased by 15.7% to $1.45. The market value of their outstanding shares is at $3.4 million. </li>
<li>BeyondSpring (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BYSI#NASDAQ">BYSI</a>) shares declined by 14.01% to $2.21. The market value of their outstanding shares is at $89.0 million. </li>
<li>GlucoTrack (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GCTK#NASDAQ">GCTK</a>) shares decreased by 12.85% to $1.96. The market value of their outstanding shares is at $10.7 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

BBLG

BYSI

GCTK

OSTX

RNAZ

SNGX

TNFA

VRCA

WINT

12 Health Care Stocks Moving In Thursday's Intraday Session

U.S. stocks traded mixed midway through trading, with the Nasdaq Composite gaining around 0.2% on Thursday.
Following the market opening Thursday, the Dow traded up 0.16% to 17,954.10 while the NASDAQ gained 0.43% to 18,002.24. The S&amp;P 500 also fell, dropping, 0.03% to 5,707.82.
Check This Out: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/10/41161390/wall-streets-most-accurate-analysts-spotlight-on-3-defensive-stocks-delivering-high-divi">Wall Street&#8217;s Most Accurate Analysts Spotlight On 3 Defensive Stocks Delivering High-Dividend Yields</a>
Leading and Lagging Sectors Information technology shares jumped by 1.3% on Thursday.
In trading on Thursday, materials shares dipped by 0.9%.
Top Headline
The S&amp;P Global services PMI was revised lower to 55.2 in September compared to a preliminary reading of 55.4, and versus a reading of 55.7 in August.
The S&amp;P Global U.S. composite PMI sipped to 54 in September versus a preliminary reading of 54.4, and versus 54.6 in August.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>Elevai Labs Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ELAB#NASDAQ">ELAB</a>) shares shot up 67% to $0.1416 after the company announced its subsidiary, Elevai Biosciences, filed two patent applications for its lead candidate, EL-22, aimed at treating muscle loss in obese patients.</li>
<li>Shares of Theriva Biologics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TOVX#NASDAQ">TOVX</a>) got a boost, surging 47% to $1.8253 after the company announced the Data and Safety Monitoring Committee&#8217;s review outcome for its Phase 1b/2a clinical trial of SYN-004. The DSMC has recommended the study proceed to enroll cohort 3.</li>
<li>AMTD Digital Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HKD#NYSE">HKD</a>) shares were also up, gaining 30% to $5.09.</li>
</ul>
Equities Trading DOWN
<ul>
<li>AngioDynamics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANGO#NASDAQ">ANGO</a>) shares dropped 19% to $6.21 following first-quarter results.</li>
<li>Shares of Kaixin Holdings &nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KXIN#NASDAQ">KXIN</a>) were down 11% to $0.3042. Shares of US-listed Chinese stocks traded lower as the sector pulled back from recent strength. These companies rallied after the People&#8217;s Bank of China announced a new stimulus package ahead of the Golden Week holidays.</li>
<li>Ingevity Corporation &nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NGVT#NYSE">NGVT</a>) was down, falling 14% to $32.22 as the company said John Fortson has departed as president and CEO and from the board of directors of the company, effective as of Oct. 2.</li>
</ul>
Commodities In commodity news, oil traded up 4.3% to $73.14 while gold traded down 0.1% at $2,667.50.
Silver traded up 0.3% to $32.015 on Thursday, while copper fell 2% to $4.5540.
Euro zone
European shares were mostly lower today. The eurozone's STOXX 600 fell 0.79%, Germany's DAX fell 0.69% and France's CAC 40 fell 0.97%. Spain's IBEX 35 Index rose 0.18%, while London's FTSE 100 fell 0.07%.
Producer prices in the Eurozone rose 0.6% month-over-month in August compared to a revised 0.7% increase in July. The HCOB Eurozone composite PMI was revised higher to 49.6 in September versus a preliminary reading of 48.9.
The S&amp;P Global UK services PMI declined to 52.4 in September from 53.7 in the previous month, while German services PMI fell to 50.6 in September from 51.2 a month ago.
Asia Pacific Markets
Asian markets closed mixed on Thursday, with Japan's Nikkei 225 gaining 1.97%, Hong Kong's Hang Seng Index falling 1.47% and India's BSE Sensex dipping 2.10%.
The au Jibun Bank Japan services PMI was revised lower to 53.1 for September, versus a preliminary reading of 53.9.
Economics
<ul>
<li>U.S. initial jobless claims increased by 6,000 from the prior week to 225,000 during the week ended Sept. 28, compared to market estimates of 220,000.</li>
<li>The S&amp;P Global services PMI was revised lower to 55.2 in September compared to a preliminary reading of 55.4, and versus a reading of 55.7 in August.</li>
<li>The S&amp;P Global U.S. composite PMI sipped to 54 in September versus a preliminary reading of 54.4, and versus 54.6 in August.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/10/41160677/top-3-consumer-stocks-which-could-rescue-your-portfolio-this-quarter">Top 3 Consumer Stocks Which Could Rescue Your Portfolio This Quarter</a></li>
</ul>

KXIN

Crude Oil Jumps Over 4%; US Services PMI Revised Lower

AngioDynamics shares are trading lower after the company reported worse-than-expected Q1 revenue results.

U.S. stocks were mostly lower, with the Dow Jones index falling around 300 points on Thursday.
Shares of AngioDynamics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANGO#NASDAQ">ANGO</a>) fell sharply during Thursday's session following <a href="https://www.benzinga.com/quote/ANGO/earnings">first-quarter results</a>.
AngioDynamics posted first-quarter adjusted loss of 11 cents per share, compared to market estimates of a loss of 15 cents per share. The company's quarterly sales came in at $67.491 million versus expectations of $67.933 million.
AngioDynamics shares dipped 15.6% to $6.45 on Thursday.
Here are some other big stocks recording losses in today's session.
<ul>
<li>Youdao, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DAO#NYSE">DAO</a>) shares dipped 14.6% to $5.08.</li>
<li>Ingevity Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NGVT#NYSE">NGVT</a>) shares declined 12.6% to $32.74 as the company said John Fortson has departed as president and CEO and from the board of directors of the company, effective as of Oct. 2.</li>
<li>Hims &amp; Hers Health, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NASDAQ">HIMS</a>) fell 11.1% to $16.85 in possible sympathy with Eli Lilly after the FDA announced their weight-loss drug shortage has ended.</li>
<li>Levi Strauss &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LEVI#NYSE">LEVI</a>) declined 9.1% to $19.14 after the company reported worse-than-expected third-quarter sales results and issued its FY24 adjusted EPS guidance with its midpoint below estimates. The company began a strategic review for its Dockers brand and is exploring a potential sale or other strategic transactions.</li>
<li>Joby Aviation, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JOBY#NYSE">JOBY</a>) dipped 8.8% to $5.59. Toyota announced plans to invest $500 million in Joby Aviation.</li>
<li>Bilibili Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BILI#NASDAQ">BILI</a>) shares fell 8.2% to $27.23. Shares of US-listed Chinese stocks traded lower as the sector pulled back from recent strength. These companies rallied after the People&#8217;s Bank of China announced a new stimulus package ahead of the Golden Week holidays.</li>
<li>Wolfspeed, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WOLF#NYSE">WOLF</a>) dipped 7.5% to $8.45 after Mizuho downgraded the stock from Neutral to Underperform and cut its price target from $17 to $8.</li>
<li>GDS Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GDS#NASDAQ">GDS</a>) fell 6.4% to $21.51.</li>
<li>Weibo Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WB#NASDAQ">WB</a>) dipped 5% to $10.65. Shares of US-listed Chinese stocks traded lower as the sector pulled back from recent strength.</li>
<li>Baidu, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIDU#NASDAQ">BIDU</a>) fell 4% to $110.49. Shares of US-listed Chinese stocks traded lower as the sector pulled back from recent strength.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/news/24/10/41162047/top-2-tech-and-telecom-stocks-that-are-ticking-portfolio-bombs">Top 2 Tech And Telecom Stocks That Are Ticking Portfolio Bombs</a></li>
</ul>

BIDU

BILI

Hims & Hers Health, Inc. Class A Common Stock

HIMS

JOBY

WOLF

AngioDynamics, Ingevity, Levi Strauss And Other Big Stocks Moving Lower On Thursday

Sentiment continues to be cautious as traders play the &#8220;wait-and-watch&#8221; game until they see off <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41148891/jobs-report-in-focus-will-slower-growth-push-the-fed-toward-november-interest-rate-">Friday&#8217;s non-farm payroll data.</a> The index futures traded moderately lower early Thursday. The weekly jobless claims data along with the ongoing tensions in the Middle East and the status of the dockworkers strike are among the key focal items for traders. The S&amp;P 500 has gained in all but one month so far this year and the momentum is supporting the market even as it navigates through another air pocket centered this time mainly around geopolitics.
Oil&#8217;s extended run could keep energy stocks buoyant and artificial intelligence stalwart Nvidia Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) traded higher in premarket, while electric-vehicle stocks have decelerated.
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Futures</td>
<td>Performance (+/-)</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>-0.44%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>-0.33%</td>
</tr>
<tr>
<td>Dow</td>
<td>-0.36%</td>
</tr>
<tr>
<td>R2K</td>
<td>-0.67%</td>
</tr>
</tbody>
</table>
</figure>
In premarket trading on Thursday,&nbsp;the SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) moved down 0.30% to $567.15 and the&nbsp;Invesco QQQ ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) slipped 0.39% to $480.09, according to&nbsp;<a href="https://benzinga.grsm.io/lxquj26b2sag" target="_blank" rel="noreferrer noopener">Benzinga Pro data</a>.
Cues From Last Session:
U.S. stocks closed Wednesday&#8217;s session marginally higher, as the market overcame early jitters set in motion by a stronger-than-expected private payrolls report and the ongoing headwinds such as the Middle East tensions and dockworkers&#8217; strike. After recouping early losses, the averages moved in a narrow range around the unchanged line before ending slightly higher.
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Index</td>
<td>Performance (+/)</td>
<td>Value</td>
</tr>
<tr>
<td>Nasdaq Composite</td>
<td>+0.08%</td>
<td>17,925.12</td>
</tr>
<tr>
<td>S&amp;P 500 Index</td>
<td>+0.01%</td>
<td>5,709.54</td>
</tr>
<tr>
<td>Dow Industrials</td>
<td>+0.09%</td>
<td>42,196.52</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>-0.09%</td>
<td>2,195.01</td>
</tr>
</tbody>
</table>
</figure>
Seven of the 11 S&amp;P 500 sectors ended in the red, while energy stocks rallied strongly and IT stocks found moderate buying interest. Utility and financial stocks rose marginally.
Insights From Analysts:
The non-farm payrolls report due on Friday is expected to show job gains of 150,000 for September, up from 142,000 in August. JPMorgan Trading Desk <a href="https://x.com/TradingThomas3/status/1841607537445183928">predicts </a>a volatile Friday, with the S&amp;P 500 Index potentially moving either side of the flat line in a range of a 2% decline to a 1.5% gain depending on how the numbers pan out,
<ul>
<li>job gains over 20,000 &#8211; flat to 0.5% gain</li>
<li>160,000-20,000 &#8211; 1%-1.5% gain</li>
<li>140,000-160,000 &#8211; 0.75%-1.25%</li>
<li>110,000 &#8211; 140,000 &#8211; 0.5%-1.5% drop</li>
<li>less than 110,000 &#8211; 1.25%-2% drop</li>
</ul>
See also: <a href="https://www.benzinga.com/money/best-futures-trading-software">Best Futures Trading Software</a>
Upcoming Economic Data:
<ul>
<li>The Labor Department will release the weekly jobless claims data at 8:30 a.m. EDT. Economists, on average, expect the number of individuals claiming unemployment benefits to come in at 220,000 in the week ended Sept. 28, up from 218,000 in the previous reporting week.</li>
<li>S&amp;P Global is due to release its final service sector manufacturing index at 9:45 a.m. EDT. The flash reading released in mid-September came in at 55.4, up from 54.2 in August.</li>
<li>The Institute for Supply Management&#8217;s non-manufacturing PMI, due at 10 a.m. EDT, is expected at 51.7 in September, almost flattish at 51.5 reported for August.</li>
<li>The Commerce Department will release the factory goods orders report at 10 a.m. EDT. The consensus estimate calls for unchanged orders for August relative to September when orders climbed 5% month-over-month.</li>
<li>Minneapolis Fed President Neel Kashkari is due to moderate a discussion with Atlanta Fed President Raphael Bostic at 10:40 a.m. EDT.</li>
<li>The Treasury will auction four- and eight-week bills at 11:30 a.m. EDT.</li>
</ul>
Stocks In Focus:
<ul>
<li>Levi Strauss &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LEVI#NYSE">LEVI</a>) slumped nearly 11% <a href="https://www.benzinga.com/premarket">in premarket trading </a>on the company&#8217;s quarterly results released after the market close on Wednesday.</li>
<li>AngioDynamics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANGO#NASDAQ">ANGO</a>) and Constellation Brands, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STZ#NYSE">STZ</a>) are due to release their <a href="https://www.benzinga.com/calendars/earnings">quarterly results ahead of the market opening.</a></li>
<li>Tesla, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) fell over 1.50%, extending its slide from Wednesday, and most electric-vehicle stocks, including Rivian Automotive, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIVN#NASDAQ">RIVN</a>), Lucid Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LCID#NASDAQ">LCID</a>) and ChargePoint Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHPT#NYSE">CHPT</a>) all traded down about 2%.</li>
<li>Plug Power Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLUG#NASDAQ">PLUG</a>) moved down 1.85% following a negative analyst action.</li>
</ul>
Commodities, Bonds And Global Equity Markets:
Crude oil futures continued their upward climb amid intensifying Middle East tensions, while gold futures fell modestly. Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) declined over 1% below the $61K mark. The yield on the 10-year Treasury note rose 2.4 points to 3.809%.
Most Asian retreated barring the Japanese, Australian, New Zealand and Malaysian markers, while China and South Korea were closed for public holidays. The major European markets lost ground in early trading.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/24/10/41159016/port-strike-enters-day-3-economist-warns-of-meaningful-impact-if-standoff-prolongs-food-beverages-li">Port Strike Enters Day 3: Economist Warns Of &#8216;Meaningful&#8217; Impact If Standoff Prolongs, Food &amp; Beverages Likely First To Feel The Pinch</a></li>
</ul>
Image Via Shutterstock

Futures

Previews

Economics

Federal Reserve

Pre-Market Outlook

$BTC

CHPT

LCID

NVDA

PLUG

RIVN

TSLA

US Stocks Staring At Another Weak Open As Traders Await Key Jobs Report; Sentiment Wavers As Oil Extends Surge Amid Middle East Tensions

Guidance

AngioDynamics Expects FY2025 Adjusted EPS Loss Of $(0.38)-$(0.42) Versus Consensus Of $(0.41)

For fiscal year 2025, the Company continues to expect:
<ul>
<li>Net sales to be in the range of $282 to $288 million, representing growth of between 4.2% &ndash; 6.4% over fiscal 2024 pro forma revenue of $270.7 million</li>
<li>Med Tech net sales are expected to grow in the range of 10% to 12%</li>
<li>Med Device net sales are expected to grow in the range of 1% to 3%</li>
<li>Gross margin to be approximately 52% to 53%</li>
<li>Adjusted EBITDA loss of $2.5 million to $0, compared to a pro forma adjusted EBITDA loss of $3.2 million in fiscal year 2024</li>
<li>Adjusted loss per share in the range of $0.38 to $0.42, compared to pro forma adjusted loss per share of $0.45 in fiscal year 2024</li>
</ul>

AngioDynamics Expects FY2025 Net Sales Of $282M-$288M Versus Consensus Of $284.367M

AngioDynamics Q1 2025 Adj. EPS $(0.11) Beats $(0.15) Estimate, Sales $67.491M Miss $67.933M Estimate

AngioDynamics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANGO#NASDAQ">ANGO</a>) will release earnings results for its first quarter, before the <a href="https://www.benzinga.com/quote/ANGO/earnings">opening bell on Thursday, Oct. 3.</a>
Analysts expect the Latham, New York-based company to report a quarterly loss at 15 cents per share, versus a year-ago loss of 12 cents per share. AngioDynamics is projected to post quarterly revenue of $67.93 million, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
On Sept. 3, AngioDynamics announced CE Mark approval for Auryon System in Europe.
AngioDynamics shares gained 0.3% to close at $7.65 on Wednesday.
Benzinga readers can access the latest analyst ratings on the <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">Analyst Stock Ratings</a> page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.
Let's have a look at how Benzinga's most-accurate <a href="https://www.benzinga.com/quote/ango/analyst-ratings">analysts have rated the company</a> in the recent period.
<ul>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/5defa41dbffdfc00019394f4/yi-chen">HC Wainwright analyst Yi Chen</a> reiterated a Buy rating with a price target of $14 on Sept. 20. This analyst has an accuracy rate of 63%.</li>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/58580533ee7bf60001bcfa0d/steven-lichtman">Oppenheimer analyst Steven Lichtman</a> upgraded the stock from Perform to Outperform with a price target of $12 on April 5. This analyst has an accuracy rate of 74%.</li>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/58933b2143eaaa0001698f4f/jayson-bedford">Raymond James analyst Jayson Bedford</a> maintained an Outperform rating and cut the price target from $12 to $10 on Jan. 9. This analyst has an accuracy rate of 71%.</li>
</ul>
Considering buying ANGO stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="526" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/03033436/image-7-1024x526.png" alt="" class="wp-image-578034" style="width:592px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/03033436/image-7-1024x526.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/03033436/image-7-300x154.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/03033436/image-7-768x395.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/03033436/image-7.png 1315w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/24/10/41156151/wall-streets-most-accurate-analysts-give-their-take-on-3-consumer-stocks-delivering-high-dividend-yi">Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Consumer Stocks Delivering High-Dividend Yields</a></li>
</ul>

Top Wall Street Forecasters Revamp AngioDynamics Price Expectations Ahead Of Q1 Earnings

The CNN Money Fear and Greed index showed an improvement in the overall market sentiment, while the index remained in the &#8220;Greed&#8221; zone on Wednesday.
U.S. stocks settled slightly higher on Wednesday, amid increasing tensions in the Middle East.
NIKE, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NKE#NYSE">NKE</a>) <a href="https://www.benzinga.com/news/earnings/24/10/41147332/nike-stock-is-tumbling-wednesday-whats-going-on">shares fell</a> around 7% on Wednesday after multiple firms cut their respective price targets on the stock following a first-quarter revenue miss.
On the economic data front, private businesses in the U.S. added 143,000 workers to their payrolls during the month of September compared to a revised 103,000 gain in August and higher than market estimates of 124,000, the ADP said.
Most sectors on the S&amp;P 500 closed on a negative note, with consumer discretionary, consumer staples, and communication services stocks recording the biggest losses on Wednesday. However, energy and information technology stocks bucked the overall market trend, closing the session higher.
The Dow Jones closed higher by around 40 points to 42,196.52 on Wednesday. The S&amp;P 500 rose 0.01% to 5,709.54, while the Nasdaq Composite gained 0.08% at 17,925.12 during Tuesday's session.
Investors are awaiting earnings results from Constellation Brands, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STZ#NYSE">STZ</a>), and AngioDynamics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANGO#NASDAQ">ANGO</a>) today.
What is CNN Business Fear &amp; Greed Index?
At a current reading of 68.4, the index remained in the &#8220;Greed&#8221; zone on Wednesday, versus a prior reading of 67.8.
The Fear &amp; Greed Index is a measure of the current market sentiment. It is based on the premise that higher fear exerts pressure on stock prices, while higher greed has the opposite effect. The index is calculated based on seven equal-weighted indicators. The index ranges from 0 to 100, where 0 represents maximum fear and 100 signals maximum greediness.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/24/10/41156151/wall-streets-most-accurate-analysts-give-their-take-on-3-consumer-stocks-delivering-high-dividend-yi">Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Consumer Stocks Delivering High-Dividend Yields</a></li>
</ul>
Photo courtesy: Shutterstock

S&P Settles Slightly Higher Despite Middle East Concerns: Fear Index Remains In 'Greed' Zone

Should investors add these stocks on their watchlist? Insider buys suggest so.

3 Stocks Insiders Are Buying Heavily In October 2024, And Why

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Incyte (INCY – Research Report), Otsuka Holdings Co (OTSKF – Rese...

Analysts Offer Insights on Healthcare Companies: Incyte (INCY), Otsuka Holdings Co (OtherOTSKF) and AngioDynamics (ANGO)

AngioDynamics (ANGO) announced the launch of an international multi-center prospective registry study to assess the long term effects of treating m...

AngioDynamics and UCLH launch study of 'long term effects' of NanoKnife System

Gradually lowering inflation and reducing borrowing rates have opened new and exciting doors for growth stocks. With a positive economic outlook, investors could keep a watchful eye on Esperion Therapeutics (ESPR), AngioDynamics (ANGO), and Fathom Holdings (FTHM) to capitalize on the growing economy. Continue Reading… With the recent Fed rate cut, slowly easing rate of inflation, and general optimism for economic growth, U.S. businesses are showing signs of strong growth prospects. Thus, it might be an opportune moment to seek high-growth stocks.
With these economic drivers in mind, investors could look into shares of growth stocks Esperion Therapeutics, Inc. (<a href="https://stocknews.com/stock/ESPR/">ESPR</a>), AngioDynamics, Inc. (<a href="https://stocknews.com/stock/ANGO/">ANGO</a>), and Fathom Holdings Inc. (<a href="https://stocknews.com/stock/FTHM/">FTHM</a>). All three stocks are priced under $10, and Wall Street analysts see substantial upsides in them.
The Federal Reserve cut its key interest rate by a quarter-point this month in response to the steady decline in the once-high inflation. A historic half-point reduction in September preceded this rate cut. The <a href="https://apnews.com/article/federal-reserve-election-inflation-trump-economy-prices-e6b837fd85cff5ad71d4e40939b97237">benchmark rate sits around 4.6%</a> right now, down from a four-decade high of 5.3%.
These rate cuts mainly aimed to combat inflation and reduce borrowing costs for consumers and businesses alike. Inflation has since fallen from a 9.1% peak in mid-2022 to a three-and-a-half-year low of <a href="https://apnews.com/article/inflation-prices-interest-rates-economy-federal-reserve-cd6d9712bfd484d6e1bc4ccb958dcf23">2.4% in September</a>. As inflation eases, the economy gets another chance to start thriving again.
The Fed plans to cut the rates once more this year and around four times in 2025 to bring inflation closer to its 2% target. However, with the economy mostly solid and Wall Street anticipating faster growth, further rate cuts may become less likely.
In this dynamic environment, growth stocks stand out for their above-average revenue growth, with companies frequently reinvesting profits to drive future expansion, making them a compelling choice for long-term investors.
Now, let us dive deep into the fundamentals of three growth stocks.
Esperion Therapeutics, Inc. (<a href="https://stocknews.com/stock/ESPR/">ESPR</a>)
ESPR is a pharmaceutical company that focuses on developing and commercializing medicines for patients suffering from elevated low-density lipoprotein cholesterol (LDL-C). Its offerings include NEXLETOL, NEXLIZET, NILEMDO, and NUSTENDI.
On May 22, ESPR and Daiichi Sankyo Europe GmbH announced the approval of NILEMDO&#xAE; and NUSTENDI&#xAE;, the European Commission (EC), for treating hypercholesterolemia and reducing the risk of adverse cardiovascular events. ESPR is set to have a significant presence in the European drug market for treating cardiac diseases and enabling newer revenue streams for the company.
For the fiscal 2024 third quarter ended September 30, ESPR's total revenues increased 52% year-over-year to $51.63 million. As of September 30, 2024, the company's cash and cash equivalents stood at $144.72 million, compared to $82.25 million on December 31, 2023.
Moreover, ESPR's total assets stood at $314.11 as of September 30, 2024, compared to $205.80 on December 31, 2023.
Analysts expect ESPR's revenue for the fiscal year ending December 2025 to increase 31.3% year-over-year to $427.99 million. Moreover, its <a href="https://www.investopedia.com/terms/e/eps.asp">EPS</a> for the same period is expected to increase significantly to $0.20. Moreover, the company topped the consensus revenue and EPS estimates in three of its four trailing quarters.
Over the past three years, ESPR's revenue and total assets have grown at CAGRs of 59.6% and 11.7%, respectively.
Shares of ESPR have surged 23.9% over the past three months and 135.9% over the past year to close the last trading session at $2.23.
Based on four Wall Street analysts offering 12-month price targets for ESPR in the last three months, the average target price is $7.76, <a href="https://www.tipranks.com/stocks/espr/forecast">indicating a 248% upside</a> from the last price.
ESPR's robust fundamentals are reflected in its <a href="https://stocknews.com/powr-ratings/">POWR Ratings</a>. The stock has an overall rating of B, which translates to a Buy in our proprietary rating system. The POWR Ratings are calculated by considering 118 different factors, each weighted to an optimal degree.
ESPR has a B grade for Growth, Value, and Quality. It is ranked #46 out of 332 stocks in the <a href="https://stocknews.com/category/biotech/">Biotech</a> industry.
<a href="https://stocknews.com/stock/ESPR/">Click here</a> to access ESPR's ratings for Stability, Momentum, and Sentiment.
AngioDynamics, Inc. (<a href="https://stocknews.com/stock/ANGO/">ANGO</a>)
ANGO is a medical technology company that designs, manufactures, and sells medical, surgical, and diagnostic devices for vascular access, peripheral vascular disease treatment, oncology, and surgical settings. Its products include oncology products like Model 1500X RF Generator, Alatus, VenaCure EVLT 1470 Pro Laser, etc.
On May 21, ANGO announced the European CE Mark approval of its AlphaVac F1885 System for the non-surgical removal of thrombi or emboli from the pulmonary arteries and the treatment of pulmonary embolism (PE). This approval broadened ANGO's reach into the European markets and established the company as one of the market leaders in the treatment of PE.
For the fiscal 2025 first quarter that ended on August 31, 2024, ANGO's net sales came in at $67.49 million. Its gross profit was reported to be $36.72 million.
Street expects ANGO's revenue to increase 7.7% year-over-year to $305.80 million for the fiscal year ending May 2026. Moreover, the company has surpassed consensus EPS estimates in three of its four trailing quarters.
Over the past three years, the company's tangible book value has grown at a 22.6% CAGR over the past three years. ANGO's shares have gained 14.2% over the past six months and 16.9% over the past nine months, closing the last trading session at $6.99.
Based on three Wall Street analysts offering 12-month price targets for ANGO in the last three months, the average target price is $13, <a href="https://www.tipranks.com/stocks/ango/forecast">indicating an 86% upside</a> from the last price.
ANGO's fundamentals are mirrored in its POWR Ratings. It has a B grade in Growth and Sentiment.
ANGO is ranked #81 out of 137 stocks in the <a href="https://stocknews.com/category/medical-devices-equipment/">Medical - Devices &amp; Equipment</a> industry.
<a href="https://stocknews.com/stock/ANGO/">Click here</a> to access ANGO's ratings for Value, Momentum, Stability, and Quality.
Fathom Holdings Inc. (<a href="https://stocknews.com/stock/FTHM/">FTHM</a>)
FTHM offers a technology-driven real estate services platform for residential brokerage, mortgage, title, insurance, and Software as a Service to brokerages and agents through its cloud-based software, intelliAgent. The company's three operational segments include: Real Estate Brokerage; Mortgage; and Technology.
On November 4, FTHM announced the acquisition of My Home Group, a leading Arizona-based brokerage ranked 27th in the nation by transaction volume. The acquisition expands Fathom's market reach, strengthens its agent network, and supports its commitment to delivering comprehensive real estate solutions nationwide.
For the fiscal 2024 third quarter that ended on September 30, FTHM's total revenue came in at $83.73 million. As of September 30, 2024, FTHM's cash and cash equivalents were reported to be $13.10 million, compared to $7.40 million on December 31, 2024.
The consensus revenue estimate of $408.92 million for the fiscal year ending December 2025 reflects a year-over-year rise of 25.6%.
Over the past five years, the company's revenue and total assets have grown at CAGRs of 27% and 91.8%, respectively. FTHM shares have gained 36.2% over the past six months, closing the last trading session at $1.92.
Based on two Wall Street analysts offering 12-month price targets for FTHM in the last three months, the average target price is $3.75, <a href="https://www.tipranks.com/stocks/fthm/forecast">indicating a 95.3% upside</a> from the last price.
FTHM's sound prospects are projected in its POWR Ratings. It has a B grade for Growth.
FTHM is ranked #32 out of 46 stocks in the <a href="https://stocknews.com/category/real-estate-services/">Real Estate Services</a> industry.
<a href="https://stocknews.com/stock/FTHM/">Click here</a> to access FTHM's ratings for Value, Stability, Quality, Momentum, and Sentiment.
What To Do Next?
Get your hands on this special report with 3 low priced companies with tremendous upside potential even in today's volatile markets:
<a href="https://report.stocknews.com/free-report/3stocks/?formplacement=artbotad_3s">3 Stocks to DOUBLE This Year &gt;</a>

<hr />
ESPR shares were trading at $2.19 per share on Thursday afternoon, down $0.04 (-1.79%). Year-to-date, ESPR has declined -26.76%, versus a 26.35% rise in the benchmark S&amp;P 500 index during the same period.
<hr><div style="clear:both;"></div> <h2>About the Author: Anushka Dutta</h2> <img src='https:/wp-content/uploads/2021/08/Anushka-Dutta_Headshot_3.jpg' style="float:left; padding:5px;width:125px;">Anushka is an analyst whose interest in understanding the impact of broader economic changes on financial markets motivated her to pursue a career in investment research.<a href="https://stocknews.com/authors/?author=anushka-dutta">More...</a>The post <a href=https://stocknews.com/news/espr-ango-fthm-3-growth-stocks-under-10-that-analysts-predict-will-skyrocket/>3 Growth Stocks Under $10 That Analysts Predict Will Skyrocket</a> appeared first on <a href=https://stocknews.com/>StockNews.com</a>

3 Growth Stocks Under $10 That Analysts Predict Will Skyrocket

AngioDynamics ( ($ANGO) ) has provided an announcement. Shareholders of AngioDynamics, Inc. have approved the amendment of the 2020 Equity Incentiv...

AngioDynamics Shareholder Approvals and Director Elections

AngioDynamics (ANGO) announced it received U.S. FDA 510(k) clearance for the NanoKnife System for prostate tissue ablation. Published first on TheF...

AngioDynamics receives FDA 510(k) clearance for NanoKnife System

Get caught up quickly on the top news and calls moving stocks with these five Top Five lists. 1. STOCK NEWS: Omnicom (OMC) agreed to acquire Interp...

Omnicom to acquire Interpublic, China to investigate Nvidia: Morning Buzz

Canaccord Genuity analyst John Young CFA has maintained their bullish stance on ANGO stock, giving a Buy rating today. John Young CFA has given his...

AngioDynamics Receives FDA Clearance for NanoKnife System, Poised for Growth with New Market Opportunities and Clinical Success

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on AbbVie (ABBV – Research Report), Protagonist Therape...

Analysts Are Bullish on Top Healthcare Stocks: AbbVie (ABBV), Protagonist Therapeutics (PTGX)

AAPL

ABBV

AMZN

BNED

ESPR

ETON

FTHM

HOOD

INCY

MDLZ

MOMO

MSFT

NXPL

OTSKF

PLTR

POST

PRCH

PTGX

PYPL

RDDT

REAL

RIOT

RVNC

SATL

TTSH

VWAGY

VWAPY

Press Releases

AngioDynamics Reports Fiscal Year 2024 Fourth Quarter and Full-Year Financial Results

AngioDynamics to Participate in Upcoming Investor Conferences

AngioDynamics Announces CE Mark Approval in Europe for the Auryon System

AngioDynamics to Report Fiscal 2025 First Quarter Financial Results on October 3, 2024

AngioDynamics Initiates RECOVER-AV Clinical Trial Assessing AlphaVac F18⁸⁵ System in Treatment of Pulmonary Embolism and Long-Term Functional Outcomes

AngioDynamics Reports Fiscal Year 2025 First Quarter Financial Results

AngioDynamics Announces American Medical Association's CPT® Editorial Panel Grants Category I CPT® for Irreversible Electroporation (IRE) in Prostate and Liver

AngioDynamics and University College London Hospital Launch International Multi-Center Study to Assess Long Term Effects of Treatment with The NanoKnife® System

AngioDynamics Receives FDA Clearance for The NanoKnife® System for Prostate Tissue Ablation

AngioDynamics to Report Fiscal 2025 Second Quarter Financial Results on January 8, 2025 and Host Virtual NanoKnife Investor Event

Comments

AngioDynamics

Interés en corto

AngioDynamics (NASDAQ:ANGO) Bolsa, Informe de interés en corto

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL